Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care population

Allergy and Asthma Proceedings

Volumn 30, Issue 2, 2009, Pages 148-157

  Broder, Michael S ^a   Chang, Eunice Y ^a   Ory, Caron ^a   Kamath, Tripthi ^b   Sapra, Sandhya ^b  

^a PARTNERSHIP FOR HEALTH ANALYTIC RESEARCH   (United States)

^b GENENTECH INC   (United States)

Author keywords

Adherence; Asthma; Cohort; Fluticasone; Insurance claim review; Omalizumab; Persistence; Propensity score; Route of administration; Salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; ANDROSTANE DERIVATIVE; DRUG DERIVATIVE; FLUTICASONE; MONOCLONAL ANTIBODY; SALBUTAMOL; SALMETEROL;

ADULT; ALLERGY; ARTICLE; ASTHMA; COMORBIDITY; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT COMPLIANCE; TREATMENT OUTCOME; ADOLESCENT; ANIMAL; COHORT ANALYSIS; COMPARATIVE STUDY; HEALTH INSURANCE; INHALATIONAL DRUG ADMINISTRATION; INJECTION; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ALBUTEROL; ANDROSTADIENES; ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 67650504656     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3190     Document Type: Article

References (33)

1. American Lung Association. Trends in asthma morbidity and mortality May 2005. American Lung Association, New York, 2005.
2. Redd S. Asthma in the United States: Burden and current theories. Environ Health Perspect 110(suppl 4):557-560, 2002.
3. World Health Organization. Adherence to long-term therapies: Evidence for action. World Health Organization, Geneva, 2003.
4. Osterberg L, and Blaschke T. Adherence to medication. N Engl J Med 353:487-497, 2005.
5. Horne R, and Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555-567, 1999.
6. Lacasse Y, Archibald H, Ernst P, and Boulet LP. Patterns and determinants of compliance with inhaled steroids in adults with asthma. Can Respir J 12:211-217, 2005.
7. Soriano JB, Rabe KF, and Vermeire PA. Predictors of poor asthma control in European adults. J Asthma 40:803-813, 2003.
8. Jones C, Santanello NC, Boccuzzi SJ, et al. Adherence to prescribed treatment for asthma: Evidence from pharmacy benefits data. J Asthma 40:93-101, 2003.
9. Bukstein DA, Bratton DL, Firriolo KM, et al. Evaluation of parental preference for the treatment of asthmatic children aged 6 to 11 years with oral montelukast or inhaled cromolyn: a randomized, open-label, crossover study. J Asthma 40:475-485, 2003.
10. Bukstein DA, Henk HJ, and Luskin AT. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 23:1589-1600, 2001.
11. Harley CR, Frytak JR, and Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 9(suppl 6):S136-S143, 2003.
12. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: Methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci 48:5052-5057, 2007.
13. Quigley HA, Friedman DS, and Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: The Glaucoma Adherence and Persistency Study. Ophthalmology 114:1599-1606, 2007.
14. Laforest L, Van Ganse E, Devouassoux G, et al. Management of asthma in patients supervised by primary care physicians or by specialists. Eur Respir J 27:42-50, 2006.
15. Schatz M, Zeiger RS, Vollmer WM, et al. Development and validation of a medication intensity scale derived from computerized pharmacy data that predicts emergency hospital utilization for persistent asthma. Am J Manag Care 12:478-484, 2006.
16. O'Malley AS, Pham HH, Schrag D, et al. Potentially avoidable hospitalizations for COPD and pneumonia: The role of physician and practice characteristics. Med Care 45:562-570, 2007.
17. Hwang W, Weller W, Ireys H, and Anderson G. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood) 20:267-278, 2001.
18. Rosenbaum P, and Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983.
19. Rosenbaum P, and Rubin D. Reducing bias in observational studies using subclassifications on the propensity score. J Am Stat Assoc 79:516-524, 1984.
20. Genentech, Inc. Omalizumab (Xolair) prescribing information. South San Francisco, CA; July 2008.
21. GlaxoSmithKline. Advair Diskus prescribing information. Research Triangle Park, NC; April 2008.
22. Ory C, Fontes C, Williams S, et al. An evaluation of the factors associated with statin dose management and low-density liproprotein-cholesterol goal attainment. Dis Manag Health Outcomes 14:32-44, 2006.
23. National Institutes of Health. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute, National Institutes of Health (NHLBI), Bethesda, MD, 2007.
24. Bender B, Milgrom H, and Rand C. Nonadherence in asthmatic patients: Is there a solution to the problem? Ann Allergy Asthma Immunol 79:177-185, quiz 185-176, 1997.
25. Milgrom H, Bender B, Ackerson L, et al. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 98:1051-1057, 1996.
26. Schmaling KB, Afari N, and Blume AW. Predictors of treatment adherence among asthma patients in the emergency department. J Asthma 35:631-636, 1998.
27. Bender BG, Pedan A, and Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol 118:899-904, 2006.
28. Schwartzman S, and Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 6(suppl 2):S19-S23, 2004.
29. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis 38(suppl 5):S402-S408, 2004.
30. Garner P, Smith H, Munro S, and Volmink J. Promoting adherence to tuberculosis treatment. Bull World Health Organ 85:404-406, 2007.
31. DiMatteo MR. Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Med Care 42:200-209, 2004.
32. Haynes RB, Yao X, Degani A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2005, Issue 4. Art no. CD000011.pub2. DOI 10.1002/14651858.CD000011.pub2.
33. Horne R. Compliance, adherence, and concordance: Implications for asthma treatment. Chest 130(suppl 1):65S-72S, 2006.